Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma. J of Skin [Internet]. 2018 Dec. 17 [cited 2025 Oct. 13];2:S77. Available from: https://skin.dermsquared.com/skin/article/view/473